目的 探讨粪便SDC2基因甲基化检测在结直肠肿瘤早期检测中的价值。方法 收集2018年1月—2018年12月收治的134例入组人群的病历资料,观察和比较粪便SDC2基因甲基化和血清癌胚抗原（CEA）两种检测方法对结直肠肿瘤诊断的灵敏度和特异度。结果 134例入组人群中,正常86例,结直肠腺瘤22例,结直肠癌26例。SDC2基因甲基化检测（长安心）阳性45例,阴性89例,血清CEA检测阳性16例,阴性118例。26例结直肠癌中SDC2基因甲基化检测阳性23例（88.46%）,血清CEA检测阳性7例（26.92%）,SDC2基因甲基化检测灵敏度高于血清CEA检测（P<0.001）。22例腺瘤患者中,SDC2基因甲基化检测阳性高于血清CEA检测（31.82% vs.4.54%,P =0.042）。结论 相比血液CEA检测,粪便SDC2基因甲基化检测诊断结直肠癌及癌前病变有较高灵敏度,有待于扩大样本量对结直肠肿瘤早期诊断中价值作深入探讨。
李创坤
,
黄颖烽
,
邹瞭南
,
李筱颖
,
罗杰
,
牛凤
,
赵日升
,
王怀明
,
王辉
,
黄榕康
. 粪便SDC2基因甲基化检测在结直肠肿瘤早期检测中的应用价值[J]. 外科研究与新技术（中英文）, 2020
, 9(1)
: 10
-13
.
DOI: 10.3969/j.issn.2095-378X.2020.01.003
Objective To investigate the value of fecal SDC2 gene methylation test in early colorectal tumor diagnosis. Methods Medical records data of 134 enrolled patients were collected from six hospitals from January 2018 to December 2018. The sensitivity and specificity between fecal SDC2 gene methylation test and serum carcinoembryonic antigen (CEA) test for early colorectal tumor diagnosis were compared. Results Of the 134 enrolled cases, 86 cases were without colorectal tumors, 22 cases with colorectal adenoma, and 26 cases with colorectal cancer. Fecal SDC2 gene methylation was detected positive in 45 patients and negative in 89 patients. Serum CEA was detected positive in 16 patients and negative in 118 patients. In the 26 patients with colorectal cancer, the positive rate of SDC2 gene methylation (88.46%) was higher than that of serum CEA (27.59%), indicating that the sensitivity of SDC2 gene methylation test was higher than that of serum CEA test for patients with colorectal cancer (P<0.001). In the 22 patients with colorectal adenoma, the positive rate of SDC2 gene methylation was higher than that of serum CEA (22.73% vs. 4.54%, P=0.185). Conclusion Compared with serum CEA test, fecal SDC2 gene methylation test has a higher sensitivity in the diagnosis of colorectal tumor and precancerous lesions, and its role in the early diagnosis of colorectal tumor requires to be investigated in a larger sample size.
[1] 夏晨静, 陈志荣. 粪便DNA甲基化检测对结直肠癌诊断及预后评估临床价值研究进展[J]. 临床军医杂志, 2019, 47(6):657-659.
[2] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[3] Chen W, Zheng R, Zeng H, et al.The incidence and mortality of major cancers in China, 2012[J]. Chin J Cancer,2016,35(1):73.
[4] 王裴,张明鑫,张超,等.粪便DNA甲基化检测在结直肠癌早期诊断中的研究进展[J].现代肿瘤医学,2015,23(6):874-880.
[5] 刘艳枚,杨梦,林金端,等.SDC2基因甲基化检测在结直肠癌早期诊断中的应用[J].深圳中西医结合杂志,2019,29(14):11-13.
[6] Kadiyska T, Nossikoff A.Stool DNA methylation assays in colorectal cancer screening[J]. World J Gastroenterol,2015,21(35):10057-10061.
[7] Ahlquist D A, Zou H, Domanico M, et al.Next-generation stool DNA test accurately detects colorectal cancer and large adenomas[J]. Gastroenterology,2012,142(2):248-256.
[8] Brenner H, Hoffmeister M, Arndt V, et al.Protection from right- and left-sided colorectal neoplasms after colonoscopy:population-based study[J]. J Natl Cancer Inst,2010,102(2):89-95.
[9] Provenzale D,Jasperson K,Ahnen D J,et al.Colorectal Cancer Screening,Version 1.2015[J]. J Natl Compr Canc Netw,2015,13(8):959-968.
[10] 文小霞,何磊.血清肿瘤标志物联合检测对结直肠癌的诊断意义[J].世界临床医学,2017,11(19):187.
[11] 矣金华,刘江,王昆华.结直肠癌CpG岛甲基化表型的研究进展[J].世界华人消化杂志,2016,24(4):558-565.
[12] 王强,郑海涛,丁德祥.结直肠癌的流行病学和筛查进展[J].中国现代医生,2008,46(18):103-104.
[13] Bosch L J, Carvalho B, Fijneman R J, et al.Molecular tests for colorectal cancer screening[J]. Clin Colorectal Cancer,2011,10(1):8-23.
[14] 张丽丽,吴建新.DNA甲基化——肿瘤产生的一种表观遗传学机制[J].遗传,2006,28(7):880-885.
[15] 赵慧霞,李秋文,董伟伟,等.粪便SEPT9基因甲基化检测在结直肠癌早期诊断中的应用研究[J].中华临床医师杂志(电子版),2012,6(10):2599-2602.
[16] Chen J,Sun H, Tang W, et al.DNA methylation biomarkers in stool for early screening of colorectal cancer[J]. J Cancer,2019,10(21):5264-5271.
[17] Castells A.Colorectal cancer screening[J].Gastroenterol Hepatol,2013,36(Suppl 2):66-72.
[18] Dickinson B T, Kisiel J, Ahlquist D A, et al.Molecular markers for colorectal cancer screening[J]. Gut,2015,64(9):1485-1494.
[19] Zou H, Allawi H, Cao X, et al.Quantification of methylated markers with a multiplex methylation-specific technology[J].Clin Chem,2012,58(2):375-383.
[20] Imperiale T F, Ransohoff D F, Itzkowitz S H, et al.Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med,2014,370(14):1287-1297.
[21] 潘世扬. DNA甲基化标志物在分子诊断与治疗中的价值[J].分子诊断与治疗杂志,2009,1(3):145-147.
